Response Biomedical reports strategic partnerships in Japan
Through these partnerships, Response’s sole distributer of the company’s B-type natriuretic peptide (BNP) products in Japan will be Alere. This arrangement will begin on Tuesday, Jan. 5. Shionogi is reported to be a long time Response business partner and will continue to provide biological reagents for these products under new licensing agreements. As part of these agreements, the BNP products will be manufactured by Response and will be distributed and rebranded as Alere Spot BNP in Japan.
“Due to the high quality performance and good reputation of the Shionospot BNP test in the Japanese market, the team at Alere Japan is eager to rebrand the product and launch the AlereTM Spot BNP test through an aggressive marketing campaign supported by our sales team covering the entire Japanese market,” Alere President Yasushi Michiuchi said.
The Shionospot Reader is marketed by Shionogi and is currently manufactured by Response. BNP tests are primarily utilized in cardiac arrest cases in order to determine diagnosis-related properties and to assist in case management.
“We are pleased to report this new business relationship with Alere Japan,” Barbara Kinnaird, CEO of Response, said. “We have worked with Shionogi over the last six months to find a new strategic partner to market Shionospot BNP in Japan. We have identified Alere Japan as the most suitable partner since Alere is the world leader in BNP testing and they do not have a competing BNP product registered in Japan. We believe that Alere Japan has the resources and commitment to improve our business in the Japanese market.”